Clinical Strategies and Therapeutics for Human Monkeypox Virus: A Revised Perspective on Recent Outbreaks
Viruses · 12.07.2023 · 15 (7) · 1533
DOI: 10.3390/v15071533 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 12.07.2023. Verfasst von Nilanjan Ghosh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, West Bengal, India. Hauptthemen laut MEDLINE: Mpox, Monkeypox. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
An enveloped double-stranded DNA monkeypox virus (MPXV) is a causative agent of the zoonotic viral disease, human monkeypox (HMPX). MPXV belongs to the genus Orthopoxviridae, a family of notorious smallpox viruses, and so it shares similar clinical pathophysiological features. The recent multicountry HMPX outbreak (May 2022 onwards) is recognized as an emerging global public health emergency by the World Health Organization, shunting its endemic status as opined over the past few decades. Re-emergence of HMPX raises concern to reassess the present clinical strategy and therapeutics as its outbreak evolves further. Keeping a check on these developments, here we provide insights into the HMPX epidemiology, pathophysiology, and clinical representation. Weighing on its early prevention, we reviewed the strategies that are being enrolled for HMPX diagnosis. In the line of expanded MPXV prevalence, we further reviewed its clinical management and the diverse employed preventive/therapeutic strategies, including vaccines (JYNNEOS, ACAM2000, VIGIV) and antiviral drugs/inhibitors (Tecovirimat, Cidofovir, Brincidofovir). Taken together, with a revised perspective of HMPX re-emergence, the present report summarizes new knowledge on its prevalence, pathology, and prevention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Pharmacology Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, West Bengal, India.
- BioAnalytical Laboratory, Meso Scale Discovery, Rockville, MD 20850-3173, USA.
- National Institute of Technology, Warangal 506004, Telangana, India.
- Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, West Bengal, India.
- ICAR-Indian Veterinary Research Institute (IVRI), Regional Station, Palampur 176061, Himachal Pradesh, India.
- Okinawa Institute of Science and Technology, Graduate University (OIST), Onna-son, Okinawa 904-0495, Japan.
ORCID-Profile: Leena Chacko, Tanmoy Banerjee, Rajkumar Singh Kalra, Saikat Dewanjee
Zitieren
APA
Ghosh, N., Chacko, L., Vallamkondu, J., Banerjee, T., Sarkar, C., Singh, B., Kalra, R. S., Bhatti, J. S., Kandimalla, R., & Dewanjee, S. (2023). Clinical Strategies and Therapeutics for Human Monkeypox Virus: A Revised Perspective on Recent Outbreaks. Viruses, 15(7), 1533. https://doi.org/10.3390/v15071533
Vancouver
Ghosh N, Chacko L, Vallamkondu J, Banerjee T, Sarkar C, Singh B, et al. Clinical Strategies and Therapeutics for Human Monkeypox Virus: A Revised Perspective on Recent Outbreaks. Viruses. 2023;15(7):1533. doi:10.3390/v15071533
BibTeX
@article{Ghosh2023,
author = {Ghosh, Nilanjan and Chacko, Leena and Vallamkondu, Jayalakshmi and Banerjee, Tanmoy and Sarkar, Chandrima and Singh, Birbal and Kalra, Rajkumar Singh and Bhatti, Jasvinder Singh and Kandimalla, Ramesh and Dewanjee, Saikat},
title = {Clinical Strategies and Therapeutics for Human Monkeypox Virus: A Revised Perspective on Recent Outbreaks},
journal = {Viruses},
year = {2023},
volume = {15},
number = {7},
pages = {1533},
doi = {10.3390/v15071533}
}
EUVIMED